Format

Send to

Choose Destination
Breast Cancer Res Treat. 2016 Nov;160(2):197-209. Epub 2016 Sep 23.

Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.

Zheng Q1,2,3, Xia W1,2,3, Lu Q1,2,3, Hong R1,2,3, Qin G1,2,3, Xu F1,2,3, Qin T1,4,2,3, Shi Y1,2,3, Yuan Z1,2,3, Wang S5,6,7.

Author information

1
Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.
2
State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.
3
Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.
4
Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
5
Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China. wangshs@sysucc.org.cn.
6
State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China. wangshs@sysucc.org.cn.
7
Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China. wangshs@sysucc.org.cn.

Abstract

PURPOSE:

Endocrine therapy is associated with improved disease-free survival (DFS) in hormone receptor-positive breast cancer, but it is also associated with many adverse events. The aim of this study was to clarify the association between endocrine treatment-related symptoms and treatment efficacy in patients receiving adjuvant endocrine therapy.

METHOD:

EMBASE, Web of Science, PubMed, and CENTRAL databases were searched for studies that compared treatment efficacy between patients in whom adverse events did and did not occur during hormone therapy. Hazard ratios (HRs) and associated 95 % confidence intervals (CIs) for DFS and overall survival were estimated and pooled using random-effects models.

RESULTS:

Of 4665 citations identified, ten studies incorporating 32,192 patients were included in the meta-analysis. The presence of endocrine treatment-related symptoms was associated with improved DFS (HR 0.76; 95 % CI 0.68-0.85). Similar results were observed in patients with vasomotor symptoms (HR 0.76; 95 % CI 0.66-0.87) or musculoskeletal symptoms (HR 0.75; 95 % CI 0.60-0.94), in patients taking an aromatase inhibitor (HR 0.69; 95 % CI 0.57-0.85) or tamoxifen (HR 0.74; 95 % CI 0.60-0.93), and in patients with symptoms at 3-month (HR 0.74; 95 % CI 0.66-0.83), 6-month (HR 0.80; 95 % CI 0.66-0.96), or 12-month follow-up visits (HR 0.75; 95 % CI 0.68-0.83). However, no significant difference in overall survival was observed between patients with or without endocrine treatment-related symptoms (HR 0.82; 95 % CI 0.60-1.11). Sensitivity analysis excluding studies with heterogeneous factors yielded consistent results. No evidence of publication bias was observed.

CONCLUSION:

In our meta-analysis, endocrine treatment-related symptoms were shown to correlate with superior DFS and may therefore be useful in predicting treatment efficacy in patients with breast cancer receiving hormone therapy.

KEYWORDS:

Adverse events; Breast cancer; Endocrine treatment; Meta-analysis; Treatment efficacy

PMID:
27663434
DOI:
10.1007/s10549-016-3995-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center